Qi3 Ventures

Qi3 Ventures is the new name for Qi3 Accelerator. Qi3 Ventures specialises in supporting companies by providing financial investment and supporting rapid commercialisation of their products and services. Qi3 Ventures is suitable for entrepreneurs who know that they need expert and enthusiastic input from our commercial and engineering teams in addition to financial capital. Support is offered to companies in a mixture of cash (money) and business development / technical expertise (sweat). Experienced investor Nathan Hill coinvests with numerous colleagues, supported by investment analysis and other skills sourced from Qi3 and a network of technology experts and investors, who offer extensive business, technical and engineering expertise. This allows us to form a flexible ad hoc team to evaluate your proposition and then support the business. Qi3 Ventures is linked to several formal and informal Business Angel networks including Cambridge Angels and London Business Angels.

Paul Anson

Associate

10 past transactions

Honest Grapes

Seed Round in 2015
Honest Grapes is a quality and value from independent growers - a refreshing new wine marketplace.

Blu Wireless

Seed Round in 2013
Blu Wireless Technology is a Silicon IP company already demonstrating its 60GHz technology to meet this emerging WiGig standard. Targeting power sensitive mobile applications as well as long range access points, licensing their technology as a complete System IP solution. Their technology delivers data rates of multiple Gbps and ranges over 300m, but there’s a lot more to be gained by choosing to work with us. Their sophisticated system expertise, from mmWave silicon IP to intelligent, deep domain technology and market understanding, means that their partners and customers can have confidence in their promise to deliver a unique product that sets them apart from the competition, in a cost-effective and timely manner.

Ecomnova

Seed Round in 2013
Ecomnova operates as an e-commerce Web design and development, and marketing company.

Vantage Power

Series A in 2013
Vantage Power design and manufacture retrofit hybrid powertrains for buses, enabling operators to reduce their fuel consumption and emissions at a fraction of the cost of purchasing new hybrid buses. By designing the whole hybrid system - everything between the fuel tank and the wheels - we ensure optimal performance of every component, resulting in higher fuel economy, lower emissions, and greater reliability than other systems. The company's engineering team - drawn from the heavy-duty vehicle, Formula 1 and aerospace industries - is continuously challenged to develop innovative solutions, and this has culminated in a truly unique product offering.

Arquer Diagnostics

Seed Round in 2012
Arquer Diagnostics is a diagnostics company focused on the development and commercialisation of a non-invasive immunoassay diagnostic test.

LumeJet

Angel Round in 2012
LumeJet Limited develops photonic imaging printers. The company was incorporated in 2009 and is based in Coventry, United Kingdom.

Isotera

Venture Round in 2012
Isotera, UK-based LED lighting specialist. Led by CEO Marc Ottolini, Isotera has developed an intelligent LED lighting system which is designed to improve the performance of LED lights, and makes installation more affordable. The company is now working in partnership with players in the global lighting supply chain to offer end to end solutions to contractors and system integrators.

Lintbells

Venture Round in 2012
Lintbells is a producer of nutritional supplements for pets.Lintbells is now the leading pet supplements company in the UK, including two key brands: YuMOVE, the number one joint mobility supplement for dogs and cats, and YuMEGA, the UK’s number one supplement for skin and coat.

Cipher Surgical

Seed Round in 2011
Cipher Surgical Limited is a medical device company established to design, patent and globally market a unique laparoscopic medical device for maintaining a clear distal window of the laparoscope during an operative procedure.

Cytox

Seed Round in 2009
Cytox have developed a simple genetic based blood test for the assessment of risk and diagnosis of Alzheimer's Disease in the very early stages. Alzheimer's Disease affects over 26 million people world-wide and is a growing condition as people live longer. There is currently no cure for Alzheimer's Disease, but there are large international initiatives underway to find treatments with many drugs in clinical development. Cytox are commercially launching their tests in conjunction with Affymetrix (part of Thermo Fisher Scientific) to support Pharmaceutical and Biotechnology companies developing novel therapeutics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.